Global Huntington’s Disease Treatment Market- Market Overview:

The global Huntington’s disease treatment market is expected to grow from USD 365 million in 2022 to USD 1,517 million by 2030, at a CAGR of 19.5% during the Projection period 2023-2030. The growth of the Huntington’s disease treatment market is mainly driven by the rising R&D development

Huntington's disease (HD) is a hereditary disorder of the central nervous system. The disorder causes brain cells to gradually deteriorate. A physician named George Huntington described the condition as hereditary chorea in 1872. As a result, it was previously referred to as Huntington's chorea (HC). Huntington's disease usually appears when a person is between the ages of 30 and 40. Adolescent Huntington's disease occurs when symptoms of the disease begin before the age of 20. Both men and women might be affected by this illness. According to studies, one in every 10,000 people in America has HD, and over 250,000 people are at risk of inheriting the disease from a parent. As a result of the illness, affected individuals experience a wide range of symptoms. It mostly affects motor coordination (movement), intelligence (thinking), and conduct. Motor disorders include muscle movement deficiencies as well as the onset of uncontrolled, uncontrollable jerks. People with HD also have muscle contractions (dystonia) or stiffness, as well as poor walking, balance, and posture. Motor coordination loss interferes with daily activities and makes it difficult to live a regular life. The illness also causes communication and respiratory problems (dysphagia). When the motor or cognitive control centres responsible for these actions are compromised, these symptoms are unavoidable.

Sample Request: - Global Huntington’s Disease Treatment Market

market Dynamics:

Drivers:                          

• Rising Adoption of Medication

The involvement of key industry players in the search for a therapy for Huntington's disease (HD) is projected to boost market growth. This could be attributable to an increasing patient population and sickness incidence worldwide, notably in North America and Europe. The unmet need for disease-modifying drugs and other HD treatment methods is projected to boost market expansion.

Restraints:                                             

• Shortage of Drugs

The number of registered drugs for Huntington's disease is limited due to high standards and limits. This is predicted to limit market growth for the foreseeable future. Furthermore, due to the stigma associated with Huntington's disease, low levels of awareness about this disease in many parts of the world, strict drug approval restrictions, alternative therapy plans, and a limited number of approved drugs, the Huntington's disease treatment market is expected to grow slowly.

Opportunities:

• Rising R&D

Increased pharmaceutical R&D expenditure and the development of novel medications have also fueled the worldwide Huntington's disease therapeutics market's rise. Because of the scarcity of curative pharmaceuticals, manufacturers have increased their investment in R&D to discover novel treatments for Huntington's disease. Extensive pipeline medications with qualities such as high patient compliance and increased safety are also contributing to the global Huntington's disease therapeutics market's growth. Alternative therapies such as psychotherapy, speech therapy, and physiotherapy have enormous potential to contribute to the expansion of the worldwide Huntington's disease therapeutics market. Only two symptom-relieving treatments are currently approved for HD: Xenazine and Austedo.

Challenges:

• Depression

Suicide may be increased by the severe depression associated with Huntington's disease. According to certain study, the larger risk of suicide occurs before a diagnosis and in the later stages of the disease, when a person has begun to lose independence. A person with Huntington's disease eventually requires assistance with all activities of daily living and care. He or she will most likely be confined to a bed and unable to talk by the end of the disease. However, a person's comprehension of their surroundings and interactions lasts a long time.

Segmentation Analysis:

The global Huntington’s disease treatment market has been segmented based on drug type, treatment, and region.

By Drug Type

The drug type segment is antidepressants, antipsychotic drugs, tetrabenazine, tranquilizers, and others. The antipsychotic drugs segment led the largest share of the Huntington’s disease treatment market with a market share of around 36.47% in 2022. Antipsychotic drugs that treat Huntington's illness also function through an antidopaminergic mechanism. Antipsychotic medications alleviate chorea while also alleviating mental symptoms, behavioural abnormalities, and cognitive impairments in Huntington's disease patients. Ability Haldol (haloperidol) is a commonly prescribed antipsychotic drug. It has been demonstrated to alleviate chorea symptoms, although it is associated with a number of adverse effects. Atypical antipsychotics, which are second-generation antipsychotic drugs, are expected to be more tolerated than traditional treatments, with fewer Parkinson's-like side effects.

By Treatment

The treatment segment is disease-modifying therapies and symptomatic treatment. The symptomatic treatment segment led the largest share of the Huntington’s disease treatment market with a market share of around 60.3% in 2022. During the Projection period, the symptomatic treatment segment is estimated to account for the majority of the market. The segment revenue has been boosted by the relatively high availability and utilisation rate of symptom management medicines. For symptomatic management, the need for several treatments and the intervention of a multispecialty care team results in higher expense, resulting in substantial revenue generation through this category. Symptomatic therapeutic development is primarily concerned with motor dysfunction and chorea. Chorea continues to be the most prominent clinical symptom of Huntington's disease, for which the majority of treatment research have been conducted. For example, Neurocrine Biosciences stated in December 2021 that valbenazine dramatically reduced chorea in persons with Huntington's disease in a Phase 3 clinical trial titled-KINECT-HD.

Global Huntington’s Disease Treatment Market - Sales Analysis.

The sale of the Huntington’s disease treatment market expanded at a CAGR of 17.4% from 2016 to 2022.

The projected label expansion of Ingrezza for the treatment of chorea associated with Huntington's disease, the high prevalence of HD in Western nations, and a robust product pipeline of disease-modifying treatments are considered to be important market drivers. HD affects around 30,000 persons in North America, with an incidence of 5.7 per 100,000. Children with HD are far more rare, accounting for only 5% to 10% of all cases. It affects up to ten persons out of every 100,000 in Europe. The projected label expansion of Ingrezza for the treatment of chorea associated with Huntington's disease, the high prevalence of HD in Western nations, and a robust product pipeline of disease-modifying treatments are considered to be important market drivers.

HD affects around 30,000 persons in North America, with an incidence of 5.7 per 100,000. Children with HD are far more rare, accounting for only 5% to 10% of all cases. It affects up to ten persons out of every 100,000 in Europe. Annexon, Inc. is developing ANX005, an investigational monoclonal antibody that targets aberrant C1q activity in complement-mediated neurodegenerative disorders such as Huntington's disease. This novel medicine is delivered intravenously (IV) and is designed to reduce C1q as well as the entire classical complement system. The business plans to begin a phase 2 clinical trial of ANX005 for the treatment of HD patients in November 2020. Stem cell therapy is also gaining popularity as a possible treatment for HD.

Thus, owing to the aforementioned factors, the global Huntington’s disease treatment market is expected to grow at a CAGR of 19.5% during the Projection period from 2023 to 2030.

By Regional Analysis:

The regions analyzed for the Huntington’s disease treatment market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region dominated the Huntington’s disease treatment market and held a 38.2% share of the market revenue in 2022.

• The North America region witnessed a major share. The increased illness burden is to blame for the expected large percentage of North America. According to Cleveland Clinic data published in January 2020, this condition affects approximately 30,000 Americans. Disease prevalence in North America was 5.7 per 100,000 individuals. Furthermore, market participants are playing an important role in stimulating market growth by expanding their product portfolios and pipeline programmes. For example, in June 2021, the US-based business Galyan Bio announced plans to begin a clinical trial with Bicoll GmbH for its small molecules candidate aimed at delaying the progression of Huntington's disease.
• Asia-Pacific is anticipated to experience significant growth during the Projection period. Due to increased product penetration, untapped potential, and the growing prevalence of the condition in developing countries over the Projection period. A growing number of government efforts aimed at improving the health of the populace are predicted to fuel the region's market growth. The market for Huntington's disease therapy, on the other hand, is competitive, which may limit its expansion in this region. Teva Pharmaceutical Industries Ltd., for example, filed a patent action against Indian generic producers Lupin Ltd. and AurobindoPharma Ltd. in July 2021 to prevent them from launching a generic version of Austedo on the market.

Global Huntington’s Disease Treatment Market - Country Analysis:

• Germany

Germany's Huntington’s disease treatment market size was valued at USD 0.75 million in 2022 and is expected to reach USD 1.19 million by 2030, at a CAGR of 6% from 2023 to 2030. Because of the ageing population, the prevalence of the targeted population, the emphasis on aesthetic appearance, and the expansion of the research base. Whereas an increase in vulnerable immune challenged patient population is driving market growth in this area.

• China

China’s Huntington’s disease treatment market size was valued at USD 0.78 million in 2022 and is expected to reach USD 1.26 million by 2030, at a CAGR of 6.2% from 2023 to 2030. Teva Pharmaceutical Industries Ltd. gained NMPA approval for Austedo in China in May 2020 for the treatment of HD chorea. After the United States, China is the second country to ratify AUSTEDO. The company's regional development is likely to result in a greater patient base and revenue growth.

• India

India's Huntington’s disease treatment market size was valued at USD 0.60 million in 2022 and is expected to reach USD 0.96 million by 2030, at a CAGR of 6.1% from 2023 to 2030. This increase is attributable to the disease's high burden, rising healthcare cost, technical breakthroughs, proactive government actions, and increased patient awareness regarding Huntington's disease treatment solutions. H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., for example, are supporting market expansion by introducing symptom management solutions.

Key Industry Players Analysis:

To increase their market position in the global Huntington’s disease treatment market business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.             

• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Raptor Pharmaceutical
• Bausch Health Companies Inc.
• Vertex Pharmaceuticals Incorporated
• Hetero
• Sun Pharmaceutical Industries Ltd.
• Lupin
• Hikma Pharmaceuticals PLC
• Reddy’s Laboratories Ltd.
• Auspex Pharmaceuticals
• Cortex Pharmaceuticals Inc
• Valeant Pharmaceuticals International Inc.

Latest Development:

• In January 2022, Ionis Pharmaceuticals, Inc. announced a collaboration with Roche to evaluate tominersen in a new Phase 2 trial for the treatment of Huntington's disease.
• In December 2021, Novartis announced the FDA Fast Track designation for branaplam (LMI070), a potential first-in-class orally administered disease-modifying medication for the treatment of Huntington's disease.
• In 2021, NeuExcell Therapeutics Inc will collaborate with Spark Therapeutics, Inc. to explore gene therapy for the treatment of HD patients. According to the terms of the deal, NeuExcell Therapeutics will receive upfront licence fees, R&D and sales milestone payments totaling up to USD 190 million, as well as extra product royalties.

Report Metrics

Report Attribute	Details
Study Period	2022-2030
Base year	2022
CAGR (%)	19.5%
Market Size	365 million in 2022
Projection period	2023-2030
Projection unit	Value (USD)
Segments covered	By Drug Type, By Treatment, and By Region.
Report Scope	Revenue Projection, competitive landscape, company ranking, growth factors, and trends Huntington’s Disease Treatment Market
Companies covered	H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical, Bausch Health Companies Inc., Vertex Pharmaceuticals Incorporated, Hetero, Sun Pharmaceutical Industries Ltd., Lupin, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Auspex Pharmaceuticals, Cortex Pharmaceuticals Inc, and Valeant Pharmaceuticals International Inc.
By Drug Type	Antidepressants Antipsychotic Drugs Tetrabenazine Tranquilizers Others
By Treatment	Disease-Modifying Therapies Symptomatic Treatment
Regional scope	North America Europe Asia-Pacific South America Middle East and Africa

Scope of the Report

Global Huntington’s Disease Treatment Market  By Drug Type:

• Antidepressants
• Antipsychotic Drugs
• Tetrabenazine
• Tranquilizers
• Others

Global Huntington’s Disease Treatment Market By Treatment:

• Disease-Modifying Therapies
• Symptomatic Treatment

Global Huntington’s Disease Treatment Market By Region:

• North America
  • USA
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
• South America
  • Brazil
  • Peru
• Middle East and Africa
  • UAE
  • South Africa
  • Saudi Arabia

Political Factors- Several factors influence the profitability of the global Huntington's disease treatment market. Changes in tax regulations, consumer protection, employment rules, and insurance duties are all political considerations that could have an impact on the industry. A change in tax legislation, for example, may need a strategy revision that either capitalise on increased government healthcare spending or accommodates diminished government subsidies. Changes in employment law, such as the 2016 laws affecting employee overtime rules, may also result in a dramatic shift in the workforce and overtime requirements.

Economical Factors- Unemployment, inflation, and interest rates are examples of economic issues affecting the financial success of healthcare organizations. These shifting circumstances may have an impact on the general population's purchasing power and state expenditure plans. For example, if a company manufactures Huntington's disease treatment for the medical field, a high unemployment rate will result in fewer people being able to relocate for treatment. Furthermore, if fewer people are able to work, they will be ineligible for job-related benefits.

Social Factor- The Huntington's disease treatment industry should be able to detect changes in the values, attitudes, and demographics of your various consumer groups. A manufacturer, for example, should be cognizant of the society it serves in order to avoid going against accepted ideas or norms. These factors must also be included in the company's marketing strategy. If an individual employs information that displays alignment with a specific sociocultural set of beliefs/values, marketing effectiveness will increase and performance will improve. Globalization has had a significant impact on Huntington's disease treatment, allowing many patients to access the best and most affordable medical care.

Technological Factors- Huntington's disease treatments are becoming more popular, and one element fueling this growth is increased R&D spending by healthcare businesses. R&D spending and the introduction of new pharmaceuticals have both surged during the last 20 years. Investments in healthcare innovation, for example, are increasing contributions to the American economy and improving the country's status as a leader in medical innovation.

Environmental Factors- Environmental sustainability strategies have both commercial and environmental benefits for companies that manufacture Huntington's disease treatment. Many businesses are now looking for environmentally sustainable construction designs, and trash disposal techniques are being reviewed. Leadership in green environmental practices demonstrates corporate social responsibility (CSR), which should be a significant component of any business plan. The application of the closed-loop, circular economy concept is becoming the norm in a number of countries. Material recycling and reuse are made easier in industries with supportive institutional structures.

Legal Factors- Consumer protection, antitrust, employment, and health and safety standards are only a few examples. These elements may have an impact on a company's operations, costs, and product demand. Failure to follow the new standards and legal processes governing Huntington's disease treatment could be the end of a firm and a market. The overall strategy should consider the legal ramifications of ongoing lawsuits, HIPAA compliance, prospective acquisitions, and other factors. There is also employment law, which is a catch-all term for various laws that protect workers' rights, such as fair compensation, equality, equity, inclusion, justice, and health and safety.

1. Introduction
   • 1. Objectives of the Study
   • 2. Market Definition
   • 3. Research Scope
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
   • 1. Porter’s Five Forces Analysis
   • 2. Value Chain Analysis
   • 3. Top Investment Pockets
     • 3.1. Market Attractiveness Analysis By Drug Type
     • 3.2. Market Attractiveness Analysis By Treatment
     • 3.3. Market Attractiveness Analysis By Region
   • 4. Industry Trends
5. Market Dynamics
   • 1. Market Evaluation
   • 2. Drivers
     • 2.1. Rising Adoption of Medication
   • 3. Restraints
     • 3.1. Shortage of Drugs
   • 4. Opportunities
     • 4.1. Rising R&D
   • 5. Challenges
     • 5.1. Depression

6. Global Huntington’s Disease Treatment Market Analysis and Projection, By Drug Type
   • 1. Segment Overview
   • 2. Antidepressants
   • 3. Antipsychotic Drugs
   • 4. Tetrabenazine
   • 5. Tranquilizers
   • 6. Others
7. Global Huntington’s Disease Treatment Market Analysis and Projection, By Treatment
   • 1. Segment Overview
   • 2. Disease-Modifying Therapies
   • 3. Symptomatic Treatment
8. Global Huntington’s Disease Treatment Market Analysis and Projection, By Regional Analysis
   • 1. Segment Overview
   • 2. North America
     • 2.1. U.S.
     • 2.2. Canada
     • 2.3. Mexico
   • 3. Europe
     • 3.1. Germany
     • 3.2. France
     • 3.3. U.K.
     • 3.4. Italy
     • 3.5. Spain
   • 4. Asia-Pacific
     • 4.1. Japan
     • 4.2. China
     • 4.3. India
   • 5. South America
     • 5.1. Brazil
   • 6. Middle East and Africa
     • 6.1. UAE
     • 6.2. South Africa

9. Global Huntington’s Disease Treatment Market-Competitive Landscape
   • 1. Overview
   • 2. Market Share of Key Players in the Huntington’s Disease Treatment Market
     • 2.1. Global Company Market Share
     • 2.2. North America Company Market Share
     • 2.3. Europe Company Market Share
     • 2.4. APAC Company Market Share
   • 3. Competitive Situations and Trends
     • 3.1. Technology Launches and Developments
     • 3.2. Partnerships, Collaborations, and Agreements
     • 3.3. Mergers & Acquisitions
     • 3.4. Expansions

10. Company Profiles
    • Lundbeck A/S
      • 1.1. Business Overview
      • 1.2. Company Snapshot
      • 1.3. Company Market Share Analysis
      • 1.4. Company Technology Portfolio
      • 1.5. Recent Developments
      • 1.6. SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
      • 2.1. Business Overview
      • 2.2. Company Snapshot
      • 2.3. Company Market Share Analysis
      • 2.4. Company Technology Portfolio
      • 2.5. Recent Developments
      • 2.6. SWOT Analysis
    • Raptor Pharmaceutical
      • 3.1. Business Overview
      • 3.2. Company Snapshot
      • 3.3. Company Market Share Analysis
      • 3.4. Company Technology Portfolio
      • 3.5. Recent Developments
      • 3.6. SWOT Analysis
    • Bausch Health Companies Inc.
      • 4.1. Business Overview
      • 4.2. Company Snapshot
      • 4.3. Company Market Share Analysis
      • 4.4. Company Technology Portfolio
      • 4.5. Recent Developments
      • 4.6. SWOT Analysis
    • Vertex Pharmaceuticals Incorporated
      • 5.1. Business Overview
      • 5.2. Company Snapshot
      • 5.3. Company Market Share Analysis
      • 5.4. Company Technology Portfolio
      • 5.5. Recent Developments
      • 5.6. SWOT Analysis
    • Hetero
      • 6.1. Business Overview
      • 6.2. Company Snapshot
      • 6.3. Company Market Share Analysis
      • 6.4. Company Technology Portfolio
      • 6.5. Recent Developments
      • 6.6. SWOT Analysis
    • Sun Pharmaceutical Industries Ltd.
      • 7.1. Business Overview
      • 7.2. Company Snapshot
      • 7.3. Company Market Share Analysis
      • 7.4. Company Technology Portfolio
      • 7.5. Recent Developments
      • 7.6. SWOT Analysis
    • Lupin
      • 8.1. Business Overview
      • 8.2. Company Snapshot
      • 8.3. Company Market Share Analysis
      • 8.4. Company Technology Portfolio
      • 8.5. Recent Developments
      • 8.6. SWOT Analysis
    • Hikma Pharmaceuticals PLC
      • 9.1. Business Overview
      • 9.2. Company Snapshot
      • 9.3. Company Market Share Analysis
      • 9.4. Company Technology Portfolio
      • 9.5. Recent Developments
      • 9.6. SWOT Analysis
    • Reddy’s Laboratories Ltd.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Auspex Pharmaceuticals
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Cortex Pharmaceuticals Inc
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis
    • Valeant Pharmaceuticals International Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Technology Portfolio
      • Recent Developments
      • SWOT Analysis

List of Table

1. Global Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
2. Global Antidepressants, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
3. Global Antipsychotic Drugs, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
4. Global Tetrabenazine, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
5. Global Tranquilizers, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
6. Global Others, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
7. Global Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
8. Global Disease-Modifying Therapies, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
9. Global Symptomatic Treatment, Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
10. Global Huntington’s Disease Treatment Market, By Region, 2023–2030 (USD Million)
11. North America Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
12. North America Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
13. USA Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
14. USA Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
15. Canada Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
16. Canada Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
17. Mexico Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
18. Mexico Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
19. Europe Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
20. Europe Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
21. Germany Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
22. Germany Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
23. France Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
24. France Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
25. UK Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
26. UK Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
27. Italy Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
28. Italy Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
29. Spain Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
30. Spain Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
31. Asia Pacific Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
32. Asia Pacific Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
33. Japan Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
34. Japan Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
35. China Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
36. China Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
37. India Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
38. India Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
39. South America Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
40. South America Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
41. Brazil Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
42. Brazil Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
43. Middle East and Africa Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
44. Middle East and Africa Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
45. UAE Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
46. UAE Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)
47. South Africa Huntington’s Disease Treatment Market, By Drug Type, 2023–2030 (USD Million)
48. South Africa Huntington’s Disease Treatment Market, By Treatment, 2023–2030 (USD Million)

List of Figures 

1. Global Huntington’s Disease Treatment Market Segmentation
2. Huntington’s Disease Treatment Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Huntington’s Disease Treatment Market Attractiveness Analysis By Drug Type
9. Global Huntington’s Disease Treatment Market Attractiveness Analysis By Treatment
10. Global Huntington’s Disease Treatment Market Attractiveness Analysis By Region
11. Global Huntington’s Disease Treatment Market: Dynamics
12. Global Huntington’s Disease Treatment Market Share By Drug Type (2023 & 2030)
13. Global Huntington’s Disease Treatment Market Share By Treatment (2023 & 2030)
14. Global Huntington’s Disease Treatment Market Share by Regions (2023 & 2030)
15. Global Huntington’s Disease Treatment Market Share by Company (2021)